Stock Groups

Exclusive-Illumina remedies on Grail bid ‘yet to convince’ Eu antitrust regulators, sources say -Breaking

by Mike Robinson

[ad_1]

© Reuters. FILE PHOTO A photograph of the building that is part of the Illumina headquarters in San Diego (California), U.S.A, September 1, 2021. REUTERS/Mike Blake

BRUSSELS (Reuters). Despite Illumina’s offers to reduce prices and let rivals continue to have access to its technologies, Illumina (NASDAQ :), a U.S.-based life sciences company has yet to impress EU antitrust regulators as they examine its $8 billion cash-and stock bid for Grail. According to sources familiar with the matter, these people are not convinced.

The European Commission began an investigation into this deal in July 2013 and warned of potential harm to innovation and market competition for DNA-based tests that detect cancer.

Disclaimer: Fusion MediaWe remind you that this site does not contain accurate or real-time data. CFDs are stocks, indexes or futures. The prices of Forex and CFDs are not supplied by exchanges. They are instead provided by market makers. As such, the prices might not reflect market values and could be incorrect. Fusion Media does not accept any liability for trade losses that you may incur due to the use of these data.

Fusion MediaFusion Media or any other person involved in the website will not be held responsible for loss or damages resulting from reliance on data including charts, buy/sell signals, and quotes. You should be aware of all the potential risks and expenses associated with trading in the financial market. It is among the most dangerous investment types.

[ad_2]